Aviragen Therapeutics To Present At Stifel 2016 Healthcare Conference

ATLANTA, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen's CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at 2:15pm ET in New York.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at  www.aviragentherapeutics.com or at http://wsw.com/webcast/stifel5/avir.

About Aviragen Therapeutics, Inc.

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.

Contacts:Mark ColonneseExecutive Vice President and Chief Financial OfficerAviragen Therapeutics, Inc.(678) 221-3381                                   mcolonnese@aviragentherapeutics.comBeth DelGiaccoStern Investor Relations, Inc.(212) 362-1200beth@sternir.com

Primary Logo

If you liked this article you might like

Who Wins, Who Loses in the MedImmune-Aviron Deal

Who Wins, Who Loses in the MedImmune-Aviron Deal

Biotech Bonus

Biotech Bonus

MedImmune Fattens Its Drug Pipeline by Buying Aviron

MedImmune Fattens Its Drug Pipeline by Buying Aviron

Aviron Says Flu Drug Won't Be as Late as Feared

Aviron Says Flu Drug Won't Be as Late as Feared